Home > Oncology > ASCO 2020 > Breast & Ovarian Cancer > Advanced breast cancer: locoregional therapy does not improve OS

Advanced breast cancer: locoregional therapy does not improve OS

Presented By
Prof. Seema A. Khan, Feinberg School of Medicine, USA
Conference
ASCO 2020
Trial
Phase 3, E2108
Featured video: A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). https://vimeo.com/440626033 Results from the long-awaited E2108 trial showed that, in patients with metastatic breast cancer, local therapy did not improve overall survival (OS) when compared with optimal systemic therapy alone. The addition of locoregional therapy also failed to improve 3-year progression-free survival (PFS). However, recurrence or progression was significantly higher in the systemic arm alone. With a median follow-up of 59 months, Prof. Seema Ahsan Khan (Feinberg School of Medicine, USA) presented the final follow-up data [1]. There has been a paucity of data about wheth...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on